Abstract: Provided are novel dosages for the safe and efficacious application of low intensity pulsed ultrasound (LIPUS) energy to increase testosterone in a subject. These newly discovered dosage ranges specify therapeutically effective dosages that avoid harmful and inconsistent effects of LIPUS as observed in prior art attempts to implement this technology platform. Disclosed is a novel calculation of a single, biologically relevant measure of LIPUS energy dosage. By the novel integrated dosage calculations described herein, the art is provided with a tool for comparing studies and standardizing doses across a range of instruments and administration protocols. Also provided are novel medical devices and ultrasonic applicators that enable the facile administration of LIPUS to testes of subjects.

Abstract: The treatment of various sensitive organs with low energy acoustic shockwaves has been proposed. However, the prior art is lacking in guidance as to what constitutes an efficacious minimum dosage or a safe maximum dosage for various target organs and tissues. Through extensive experimentation with cultured cells, live animals, and animal disease models, the inventors of the present disclosure have determined safe and efficacious shockwave energetic dosage ranges for vital and sensitive organs, including the brain, pancreas, kidneys, liver, and spleen, as well as for skin and subcutaneous tissues, peripheral nerves, and skeletal muscles.

Abstract: The invention provides novel hemostasis, tissue barriers, wound healing and cosmetology materials based on biocompatible carboxymethylcellulose, and methods for their preparation and use thereof.

Abstract: The treatment of various sensitive organs with low energy acoustic shockwaves has been proposed. However, the prior art is lacking in guidance as to what constitutes an efficacious minimum dosage or a safe maximum dosage for various target organs and tissues. Through extensive experimentation with cultured cells, live animals, and animal disease models, the inventors of the present disclosure have determined safe and efficacious shockwave energetic dosage ranges for vital and sensitive organs, including the brain, pancreas, kidneys, liver, and spleen, as well as for skin and subcutaneous tissues, peripheral nerves, and skeletal muscles.

Abstract: The treatment of various sensitive organs with low energy acoustic shockwaves has been proposed. However, the prior art is lacking in guidance as to what constitutes an efficacious minimum dosage or a safe maximum dosage for various target organs and tissues. Through extensive experimentation with cultured cells, live animals, and animal disease models, the inventors of the present disclosure have determined safe and efficacious shockwave energetic dosage ranges for vital and sensitive organs, including the brain, pancreas, kidneys, liver, and spleen, as well as for skin and subcutaneous tissues, peripheral nerves, and skeletal muscles.

Abstract: The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.

Abstract: The invention provides novel hemostasis, tissue barriers, wound healing and cosmetology materials based on biocompatible carboxymethylcellulose, and methods for their preparation and use thereof.

Abstract: The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.

Abstract: The treatment of various sensitive organs with low energy acoustic shockwaves has been proposed. However, the prior art is lacking in guidance as to what constitutes an efficacious minimum dosage or a safe maximum dosage for various target organs and tissues. Through extensive experimentation with cultured cells, live animals, and animal disease models, the inventors of the present disclosure have determined safe and efficacious shockwave energetic dosage ranges for vital and sensitive organs, including the brain, pancreas, kidneys, liver, and spleen, as well as for skin and subcutaneous tissues, peripheral nerves, and skeletal muscles.

Abstract: The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.

Abstract: The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.

Abstract: The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.

Abstract: The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.

Abstract: The application discloses adipose tissue-derived stem cells (ADSC) and related compositions and methods. ADSCs are useful for (i) production of insulin producing cells, (ii) treatment of diabetes, (iii) endothelial cell reconstitution, (iv) treatment of overactive bladder and urge incontinence, (v) prevention and treatment of bladder voiding dysfunction; (vi) treatment of neurogenic impotence such as that resulting from diabetes or after prostate cancer therapy; (vii) treatment of vasculogenic impotence, such as that resulting from hypertension, dyslipidemia, atherosclerosis and diabetes; (viii) the promotion of wound healing; (ix) reduction of skin wrinkling; and (x) hair growth.

Abstract: The present invention provides compositions and methods for promoting the recovery of vascular function in erectile dysfunction associated with vasculopathy by administering a composition comprising a vasoactive prostaglandin and a biocompatible polymer. In preferred embodiments, the prostaglandin composition is a topical composition comprising prostaglandin E1, a biocompatible polymer and a penetration enhancer and the topical composition is applied to the meatus at the tip of the penis. In another embodiment, the invention provides a method for increasing microvascular outgrowth at a targeted arterial segment comprising administering a prostaglandin E1 composition to produce an extracellular prostaglandin E1 concentration of about 1 micromolar to about 10 micromolar adjacent to the targeted arterial segment for about four days.

Abstract: The present invention provides compositions and methods of use for treatment of erectile dysfunction associated with neuropathy related to diabetes, prostatectomy, cysto-prostatectomy, radical cystectomy, abdominoperineal resection of the rectum, cryoablation or radiation therapy.